International Pompe Association

You are here: Home News Preliminary results from Amicus' ongoing Phase 2 open-label drug-drug interaction study

AT2220-Enzyme Replacement Therapy (ERT) Co-Administration Increases Pompe Enzyme (rhGAA) Activity in First 3 Dose Cohorts in Phase 2 Study

AT2220 Mitigates ERT-Related Immunogenicity in ex vivo Studies

Amicus Therapeutics announced additional positive preliminary results from an ongoing Phase 2 open-label drug-drug interaction study to evaluate the safety and plasma pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme® and Lumizyme®). These Phase 2 results were presented in a poster at the 17th International World Muscle Society Congress in Perth, Australia. The Company also announced initial findings from ex vivo studies to characterize the immunogenicity of Myozyme and Lumizyme with and without AT2220.

Read more in the press release: http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=712751 (external link to the web pages of Amicus Therapeutics) or http://files.shareholder.com/downloads/AMTX/2113902746x0x604757/21c184ac-0c70-4ec8-a18c-5d0c4de8ec49/FOLD_News_2012_10_11_General.pdf (PDF download).

 


Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.